Skye Sully
About Skye Sully
Skye Sully is the Director of Clinical Operations at Mirati Therapeutics, with extensive experience in clinical research across various therapeutic areas. Previously, she held leadership roles at Tocagen Inc. and has a strong background in compliance with ICH/GCP/FDA guidelines.
Current Role at Mirati Therapeutics
Skye Sully serves as the Director of Clinical Operations at Mirati Therapeutics, a position held since 2020. In this role, she oversees clinical operations, ensuring that clinical trials are conducted efficiently and in compliance with regulatory standards. Her responsibilities include managing clinical study protocols and collaborating with various stakeholders to facilitate successful trial outcomes.
Previous Experience at Tocagen Inc.
Prior to her current role, Skye Sully worked at Tocagen Inc. as Director of Clinical Operations for 11 months in 2020, following a four-year tenure as Associate Director of Clinical Operations from 2015 to 2019. During her time at Tocagen, she contributed to the management of clinical trials, focusing on operational efficiency and regulatory compliance within the organization.
Clinical Research Expertise
Skye Sully possesses extensive experience in clinical research across various therapeutic areas, including Oncology, CNS, Endocrinology, Respiratory, Gastroenterology, Immunology, Orthopedics, and Vaccines. Her broad knowledge base enables her to effectively manage clinical trials and navigate the complexities of different therapeutic landscapes.
Educational Background
Skye Sully earned a Bachelor of Arts (B.A.) in Kinesiology and Applied Physiology from the University of Colorado at Boulder, completing her studies from 1998 to 2002. This educational foundation supports her understanding of human physiology and the principles underlying clinical research.
Comprehensive Clinical Operations Experience
Skye Sully has a diverse background in clinical operations, having worked at all levels within the field, including roles as Sponsor, CRO, and Site. This experience provides her with a comprehensive perspective on the clinical research process. She has participated in all stages of clinical studies, demonstrating a thorough understanding of the clinical trial lifecycle from start-up through study closure.